<DOC>
	<DOCNO>NCT01142336</DOCNO>
	<brief_summary>A year-long randomized , double-blind , placebo-controlled trial simvastatin see produce beneficial change cerebral spinal fluid protein associate Alzheimer 's disease .</brief_summary>
	<brief_title>Effects Simvastatin Biomarkers</brief_title>
	<detailed_description>The purpose study see drug call simvastatin ( brand name Zocor ) beneficially affect level certain molecule ( protein ) spinal fluid people . The molecule investigator measure think important development Alzheimer 's disease ( AD ) , investigator test whether simvastatin change protein level associate reduce risk AD . Simvastatin approve United States Food Drug Administration ( FDA ) treatment high cholesterol reduce risk coronary artery disease . It investigational drug study . Participants randomly assign Placebo Simvastatin . The investigator participant blind . Randomization stratify age gender . This study fund National Institute Aging . The investigator expect 120 people take part study VA Puget Sound Health Care System course 2 year enrollment period . This study last 1 year . Participants ask come VA Seattle total 9 time , 2 time lumbar puncture ( also know spinal tap ) . The investigator would also like ask person know participant well ( spouse , child , sibling , good friend ) question participant 's health , memory , mood behavior , ability daily task begin end study . Participants must cognitively normal , healthy , willing lumbar puncture , need take medication control cholesterol .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Inclusion Criteria ( participant must meet follow criterion ) If female childbearing potential , must negative pregnancy test baseline , subsequent visit . Age 45 64 year inclusive . Considered cognitively normal evidence memory cognitive impairment ( MMSE &gt; 26 , Logical Memory delay recall &gt; 6 , CDR score 0 ) . Normal mildly elevate cholesterol require drug therapy base National Cholesterol Education Program Adult Treatment Panel III ( NCEP/ATPIII ) guideline . An LDL level 70mg/dL . Hamilton Depression Scale ( HAMD ) score &lt; 12 . BMI 18 34 ( exception make MD ) . In good recent general health ( i.e. , trauma infection 4 week LP ) . On stable dose nonexclusionary medication 4 week precede LP . Platelet count &gt; 100,000 . Exclusion Criteria ( participant must NOT satisfy follow condition ) Any contraindication LP , spinal deformity , severe disease infection LP region , bleed tendency , anticoagulant bloodthinning medication . Taken statin medication past 12 month . Any clinically significant laboratory abnormality . Any neurological disorder : multiple sclerosis , epilepsy , stroke , Parkinson 's , degenerative CNS disorder , neuropathy radicular involvement . Acute chronic major psychiatric disorder : schizophrenia , affective disorder , severe anxiety disorder . ( Dysthymia allow , history MDD allow currently remission ) Unstable poorly control medical problem : heart failure , diabetes ( poorly control insulin dependent ) , hypertension ( BP &gt; 160/100 ) , pulmonary disease hypoxia hypercapnia , significant liver disease know hepatitis C seropositivity , renal failure , treatment cancer past 2 year ( nonmelanoma skin cancer ) know HIV positive status . Use illegal drug alcohol abuse ( &gt; 2 drinks/day 10/week ) within past year . Concurrent participation another investigational drug study . Use exclusionary medication 4 week prior screen : Drugs could interact statin : itraconazole , ketoconazole , erythromycin , clarithromycin , HIV protease inhibitor , nefazodone , amiodarone , cyclosporine , isoniazid , quinidine , large quantity grapefruit juice ( &gt; 1 quart daily ) Central nervous system act medication : antipsychotic , antiParkinson 's disease medication , anti convulsants , CNS stimulants Chronic use benzodiazepine , sedate antihistamine , sedativehypnotic agent ( prn use allow long within 72 hour LP cognitive test ) Medications affect coagulation and/or inflammation : coumadin , potent antiinflammatory medication ( hydrocortisone , methotrexate potent immunemodulating medication ) , antiHIV medication ( Aspirin 325 mg/day allow . ) Lipidlowering drug : fibrates niacin &gt; 500mg/day ( stable dose omega3 allow ) Does subject 's family history meet follow criterion ? Both parent had/have dementia On one side family , two consecutive generation three relative had/have dementia ? One parent onset dementia age 60 ? Does subject major active autoimmune immunological disorder ?</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Prevention</keyword>
	<keyword>Spinal Fluid</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Simvastatin</keyword>
</DOC>